Trimetazidine Hydrochloride

盐酸曲美他嗪

Report date: 2026/04/28 17:54:25
NME

Base Information

Drug NameTrimetazidine Hydrochloride
Drug Alias NameTrimetazidinaTrimetazidinumTrimetazidineCardiazidineVastarel +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAcetyl-CoA C-acyltransferase inhibitors
TargetsAcetyl-CoA C-acyltransferase
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Ischemic StrokePostoperative Complications +[21] 
Global Approved IndicationsMyocardial InfarctionAngina PectorisMyocardial Ischemia
Approved Indications in ChinaAngina Pectoris
Original Approved Country/TerritoryJapan
Original Approved Date1968/06/01
Country/TerritoryCzechiaBelgiumBosnia and Herzegovina +[36] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesLaboratoires Servier
China Registration ClassN/A

Develop Information

Active CompaniesSaghmos TherapeuticsThe University Of QueenslandMinia University +[7] 
Inactive CompaniesUniversity Of The West IndiesMartin Pharmaceuticals IncPontificia Universidad Catolica De Chile +[9] 
Active IndicationsIschemic StrokeDiabetes Mellitus, Type 2Myocardial Infarction +[12] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Postoperative ComplicationsBlood Platelet Disorders +[9] 

Other Information

ATC CodeC01EB15
Related LinksWikipediaDrugBankKEGG